Literature DB >> 31750127

Cinnarizine: A Contemporary Review.

Milind Vasant Kirtane1, Anita Bhandari2, Prashant Narang3, Ravi Santani3.   

Abstract

Cinnarizine, is approved for nausea, vomiting, motion sickness, inner ear disorders and is considered as first-line pharmacotherapy for management of vertigo. It acts by anti-vasoconstrictor activity, reducing blood viscosity and reducing nystagmus in labyrinth. Lack of adequate literature on clinical evidence of cinnarizine and its combination (dimenhydrinate) in vertigo management prompted this review. A specific MEDLINE literature search strategy was designed combining Medical Subject Headings, free-text keywords (like cinnarizine and vertigo) using Boolean operators (1970-2016) for clinical studies, clinical reviews and meta-analyses of cinnarizine. Analyses of studies validated cinnarizine's efficacy in peripheral and central vertigo versus placebo or other therapies, and was well-tolerated by the patients recruited across different studies. Cinnarizine and/ or its combinations are favorable in management of vestibular disorders wherein cinnarizine acts predominantly peripherally on labyrinth and dimenhydrinate acts centrally on vestibular nuclei and associated centers in brainstem. Combination therapy of cinnarizine and/ or its combinations demonstrated a better safety profile than either of the mono-components, offering a viable therapeutic option in vertigo management. © Association of Otolaryngologists of India 2017.

Entities:  

Keywords:  Cinnarizine; Dimenhydrinate; Drug combinations; Vertigo

Year:  2017        PMID: 31750127      PMCID: PMC6841794          DOI: 10.1007/s12070-017-1120-7

Source DB:  PubMed          Journal:  Indian J Otolaryngol Head Neck Surg        ISSN: 2231-3796


  36 in total

1.  Cinnarizine in the treatment of peripheral vascular disease: mechanisms related to its clinical action.

Authors:  M B Emanuel; J A Will
Journal:  Proc R Soc Med       Date:  1977

Review 2.  Initial evaluation of vertigo.

Authors:  Ronald H Labuguen
Journal:  Am Fam Physician       Date:  2006-01-15       Impact factor: 3.292

3.  Clinical evaluation of cinnarizine in patients with cerebral circulatory deficiency.

Authors:  J B Toledo; H Pisa; M Marchese
Journal:  Arzneimittelforschung       Date:  1972-02

4.  Comparative study of the effect of Devincan and Stugeron in patients suffering from cerebrovascular diseases treated at medical departments.

Authors:  A Udvarhelyi
Journal:  Ther Hung       Date:  1978

5.  Comparison of the therapeutic efficacy of a fixed low-dose combination of cinnarizine and dimenhydrinate with betahistine in vestibular neuritis: a randomized, double-blind, non-inferiority study.

Authors:  Arne-Wulf Scholtz; Raluca Steindl; Nicole Burchardi; Irene Bognar-Steinberg; Wolfgang Baumann
Journal:  Clin Drug Investig       Date:  2012-06-01       Impact factor: 2.859

6.  Effect of betahistine dihydrochloride compared with cinnarizine on induced vestibular nystagmus.

Authors:  J R Cullen; S J Hall; R H Allen
Journal:  Clin Otolaryngol Allied Sci       Date:  1989-12

7.  A double-blind crossover study comparing betahistine and cinnarizine in the treatment of recurrent vertigo in patients in general practice.

Authors:  R B Deering; P Prescott; R L Simmons; L J Downey
Journal:  Curr Med Res Opin       Date:  1986       Impact factor: 2.580

8.  Treatment of vertebrobasilar insufficiency--associated vertigo with a fixed combination of cinnarizine and dimenhydrinate.

Authors:  Volker Otto; Bernhard Fischer; Mario Schwarz; Wolfgang Baumann; Rudolf Preibisch-Effenberger
Journal:  Int Tinnitus J       Date:  2008

9.  Betahistine or Cinnarizine for treatment of Meniere's disease.

Authors:  Jasminka Djelilovic-Vranic; Azra Alajbegovic; Merita Tiric-Campara; Aida Volic; Zehra Sarajlic; Eldina Osmanagic; Ljubica Todorovic; Omer Beslagic
Journal:  Med Arch       Date:  2012

10.  Cinnarizine and dimenhydrinate in the treatment of vertigo in medical practice.

Authors:  Arne-Wulf Scholtz; Justus Ilgner; Benjamin Loader; Bernd W Pritschow; Gerhard Weisshaar
Journal:  Wien Klin Wochenschr       Date:  2015-12-11       Impact factor: 1.704

View more
  6 in total

1.  Cinnarizine/betahistine combination vs. the respective monotherapies in acute peripheral vertigo: a randomized triple-blind placebo-controlled trial.

Authors:  Payman Asadi; Seyyed Mahdi Zia Ziabari; Alireza Majdi; Karim Vatanparast; Seyed Ahmad Naseri Alavi
Journal:  Eur J Clin Pharmacol       Date:  2019-08-16       Impact factor: 2.953

2.  Formulation and Characterization of Cinnarizine Targeted Aural Transfersomal Gel for Vertigo Treatment: A Pharmacokinetic Study on Rabbits.

Authors:  Rehab Abdelmonem; Raghda Rabe Hamed; Sally A Abdelhalim; Mohamed F ElMiligi; Mohamed A El-Nabarawi
Journal:  Int J Nanomedicine       Date:  2020-08-19

3.  Efficacy and Pharmacological Appropriateness of Cinnarizine and Dimenhydrinate in the Treatment of Vertigo and Related Symptoms.

Authors:  Fulvio Plescia; Pietro Salvago; Francesco Dispenza; Giuseppe Messina; Emanuele Cannizzaro; Francesco Martines
Journal:  Int J Environ Res Public Health       Date:  2021-04-30       Impact factor: 3.390

4.  Simultaneous estimation of dimenhydrinate, cinnarizine and their toxic impurities benzophenone and diphenylmethylpiperazine; in silico toxicity profiling of impurities.

Authors:  Nada S Abdelwahab; Fadwa H Edrees; Mohammed T Alsaadi; Noha H Amin; Ahmed S Saad
Journal:  RSC Adv       Date:  2020-10-09       Impact factor: 4.036

Review 5.  Migraine Pharmacological Treatment and Cognitive Impairment: Risks and Benefits.

Authors:  Mirella Russo; Matteo A De Rosa; Dario Calisi; Stefano Consoli; Giacomo Evangelista; Fedele Dono; Matteo Santilli; Alberto Granzotto; Marco Onofrj; Stefano L Sensi
Journal:  Int J Mol Sci       Date:  2022-09-27       Impact factor: 6.208

Review 6.  Drug-Drug Interactions in Vestibular Diseases, Clinical Problems, and Medico-Legal Implications.

Authors:  Giulio Di Mizio; Gianmarco Marcianò; Caterina Palleria; Lucia Muraca; Vincenzo Rania; Roberta Roberti; Giuseppe Spaziano; Amalia Piscopo; Valeria Ciconte; Nunzio Di Nunno; Massimiliano Esposito; Pasquale Viola; Davide Pisani; Giovambattista De Sarro; Milena Raffi; Alessandro Piras; Giuseppe Chiarella; Luca Gallelli
Journal:  Int J Environ Res Public Health       Date:  2021-12-08       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.